Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202302677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Yuhong Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, P. R. China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Nanoparticles. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Agriculture Science and Technology Innovation Fund, Demonstration Project of Modern Agricultural Machinery Equipment &Technology in Jiangsu Province.
Abstract (Originalsprache)
Oral insulin therapies targeting the liver and further simulating close‐looped secretion face significant challenges due to multiple trans‐epithelial barriers. Herein, ursodeoxycholic acid (UDCA)‐decorated zwitterionic nanoparticles (NPs) (UC‐CMs@ins) are designed to overcome these barriers, target the liver, and respond to glycemia, thereby achieving oral one‐time‐per‐day therapy. UC‐CMs@ins show excellent mucus permeability through the introduction of zwitterion (carboxy betaine, CB). Furthermore, UC‐CMs@ins possess superior cellular internalization via proton‐assisted amino acid transporter 1 (PAT1, CB‐receptor) and apical sodium‐dependent bile acid transporter (ASBT, UDCA‐receptor) pathways. Moreover, UC‐CMs@ins exhibit excellent endolysosomal escape ability and improve the basolateral release of insulin into the bloodstream via the ileal bile acid‐binding protein and the heteromeric organic solute transporter (OSTα‐ OSTβ) routes compared with non‐UDCA‐decorated C‐CMs@ins. Therefore, CB and UDCA jointly overcome mucus and intestinal barriers. Additionally, UC‐CMs@ins prevent insulin degradation in the gastrointestinal tract for crosslinked structure, improve insulin accumulation in the liver for UDCA introduction, and effectively regulate glycemia for “closed‐loop” glucose control. Surprisingly, oral ingestion of UC‐CMs@ins shows a superior effect on glycemia (≈22 h, normoglycemia) and improves postprandial glycemic levels in diabetic mice, illustrating the enormous potential of the prepared NPs as a platform for oral insulin administration in diabetes treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, P. R. China.
ORCID-Profile: Wei Chen, Hongliang Qian
Förderung
- National Natural Science Foundation of China
- Jiangsu Agriculture Science and Technology Innovation Fund
- Demonstration Project of Modern Agricultural Machinery Equipment &Technology in Jiangsu Province
Zitieren
APA
Ma, Y., Wang, W., Li, C., Han, F., He, M., Zhong, Y., Huang, D., Chen, W., & Qian, H. (2024). Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202302677
Vancouver
Ma Y, Wang W, Li C, Han F, He M, Zhong Y, et al. Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202302677
BibTeX
@article{Ma2024,
author = {Ma, Yuhong and Wang, Wei and Li, Caihua and Han, Fuwei and He, Mujiao and Zhong, Yinan and Huang, Dechun and Chen, Wei and Qian, Hongliang},
title = {Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202302677}
}
EUVIMED